Numab Therapeutics Achieves Milestone Under Its Strategic Partnership With Boehringer Ingelheim

Numab Therapeutics AG, a biotechnology company developing a pipeline of multi-specific antibodies for immunology and oncology, announced that Boehringer Ingelheim has advanced a novel T cell engager, developed under their collaboration, into preclinical development. This achievement represents an important milestone in their partnership and triggers a payment to Numab in accordance with the agreement. The new therapy is designed to target lung and gastrointestinal (GI) cancers, two of the most common and deadly forms of cancer worldwide.

Lung cancer remains the leading cause of cancer-related deaths globally, while gastrointestinal cancers, such as colorectal and stomach cancers, account for a significant proportion of cases and fatalities. Boehringer Ingelheim is working to tackle these challenges by developing breakthrough therapies that address areas of high unmet medical need and by seeking to transform cancer care through innovative approaches.

Angehrn Pavik, CEO of Numab, stated, “We are pleased that Boehringer has decided to move forward with the development of our novel T cell engager into preclinical studies, generating a milestone payment to Numab. We are also excited that the potential of our antibody platform continues to be recognized by international Pharma partners and highlights our team’s strong commitment to pursuing regional and global development collaborations, in addition to our proprietary programs.”

The collaboration between Numab and Boehringer Ingelheim was first established in 2020 through a research collaboration and worldwide licensing agreement. The partnership focuses on two main areas: the development of therapies for hard-to-treat lung and gastrointestinal cancers, and therapies for wet age-related macular degeneration (AMD), a progressive retinal disease that leads to irreversible vision loss. By combining Boehringer Ingelheim’s global expertise in research and development of innovative therapies with Numab’s advanced multi-specific antibody platform, the two companies aim to deliver new treatment options for patients facing some of the most challenging diseases.